Skip to content
Alert Sign COVID-19 Updates: New Visitor Guidelines & Vaccine Update Close Alert Box
Hackensack UMC logo
  • GIVE NOW
  • 1-844-HMH-WELL
  • Find a Doctor
  • About
  • Location
  • Team
  • News
  • Services
  • Research
  • Donate

Clinical Trials

Find a DoctorOur LocationsAwards and Accreditation

Home  › Research  ›  Trials

Search for:

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of NivolumabVersus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human EpidermalGrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer


Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole


ctDNA Study, PI Dr. Arthur Topilow Circulating Tumor DNA, Micro-RNA, and Exosomal DNA is Predictive of Relapse of Triple Receptor Negative Breast Cancer.


A Prospective Multi-site Single- Arm Phase II Study To Investigate Breast IORT – The Efficacy Of Single-Fraction Intraoperative Radiation Treatment Using A Multi-Lumen Balloon Applicator And In-Room CT Imaging For The Treatment Of Early-Stage Breast Cancer.


OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy


A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer


A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy


Single Patient IND – Compassionate Use Niraparib (MK-4827)


A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy


Diarrhea Prevention and Prophylaxis with Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel with or without Carboplatin


Posts navigation

Next
View all types of trials

Types of Cancer / Trials

  • All
  • Breast
  • Breast-Surgical Oncology
  • Gastrointestinal
  • Genito-Urinary
  • Gynecologic
  • Head and Neck
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Neuro-oncology
  • Phase 1
  • Phase 1 (GI)
  • Phase 1 (L)
  • Phase 1 (Thoracic)
  • Skin and Soft Tissue
  • Thoracic (Lung)
  • Transplant

Recently Added Trials

  • A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
  • A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma.
  • A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma
  • A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
  • A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of NivolumabVersus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human EpidermalGrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

© 2021 Hackensack Meridian Health

  • About Us
  • Careers
  • Classes & Events
  • Contact Us
  • Donate
  • Financial Practices
  • Patients & Visitors
  • Privacy
  • Terms & Conditions